CytomX Therapeutics, Inc. Current Liabilities
CytomX Therapeutics, Inc. (CTMX) had Current Liabilities of $39.86 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-06
- 2026-06-30: Liabilities, Current $39.86M.
- 2026-03-31: Liabilities, Current $34.02M.
- 2025-12-31: Liabilities, Current $46.62M.
- 2025-09-30: Liabilities, Current $41.03M.
| Period end | Liabilities, Current | Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $39.86M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $34.02M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $46.62M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $41.03M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $39.22M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $50.20M 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $85.77M 10-K · filed 2026-03-16 | |
| 2024-09-30 | $119.23M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $142.86M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $144.54M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $155.91M 10-K · filed 2025-03-06 | |
| 2023-09-30 | $146.79M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $141.38M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $151.26M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $152.61M 10-K · filed 2024-03-11 | |
| 2022-09-30 | $123.64M 10-K · filed 2023-03-27 | $97.84M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $94.64M 10-K · filed 2023-03-27 | $99.44M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $87.40M 10-K · filed 2023-03-27 | $102.77M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $77.87M 10-K/A · filed 2023-03-27 | $106.32M 10-K · filed 2022-03-01 |
| 2021-09-30 | $67.53M 10-K/A · filed 2023-03-27 | $99.77M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $60.32M 10-K/A · filed 2023-03-27 | $93.38M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $64.93M 10-K/A · filed 2023-03-27 | $98.05M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $68.11M 10-K/A · filed 2023-03-27 | $100.92M 10-K · filed 2021-02-24 |
| 2020-09-30 | $102.03M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $98.78M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $106.00M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $85.59M 10-K · filed 2021-02-24 | |
| 2019-09-30 | $76.13M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $78.67M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $96.22M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $97.91M 10-K · filed 2020-02-27 | |
| 2018-09-30 | $86.27M 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $83.21M 10-Q · filed 2018-08-08 | |
| 2018-03-31 | $69.71M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $61.15M 10-K · filed 2019-02-27 | |
| 2017-09-30 | $71.24M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $60.63M 10-Q · filed 2017-08-07 | |
| 2017-03-31 | $37.13M 10-Q · filed 2017-05-05 | |
| 2016-12-31 | $35.77M 10-K · filed 2018-03-07 | |
| 2016-09-30 | $23.68M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $22.22M 10-Q · filed 2016-08-03 | |
| 2016-03-31 | $17.00M 10-Q · filed 2016-05-06 | |
| 2015-12-31 | $15.74M 10-K · filed 2017-03-02 | |
| 2015-09-30 | $13.97M 10-Q · filed 2015-11-23 | |
| 2014-12-31 | $11.16M 10-K · filed 2016-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |